


## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

### Listing of Claims

1. canceled
2. (currently amended) A The compound of ~~claim 1~~ of the Formula Ia:



~~or a~~ and pharmaceutically acceptable ~~salt salts~~ thereof ~~and or an~~ individual ~~diastereomer~~ diastereomers thereof. ~~thereof, wherein~~

the dashed line represents an optional single bond;

Y is O or CH<sub>2</sub>;

R<sup>1</sup> is selected from 1-benzoyloxyethyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl substituted with hydroxy, and C<sub>1-6</sub>alkyl substituted with 1-6 fluoro;

R<sup>5</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl substituted with 1-6 fluoro, -O-C<sub>1-6</sub>alkyl substituted with 1-6 fluoro, chloro, bromo and phenyl;


R<sup>15</sup> is methyl or hydrogen;

R<sup>16</sup> is selected from hydrogen, C<sub>1-3</sub>alkyl optionally substituted with 1-6 fluoro,

-O-C<sub>1-3</sub>alkyl, fluoro and hydroxy; and

R<sup>18</sup> is selected from hydrogen, methyl, and methoxy.

3. (currently amended) The compound of claim 1 of the Formula Ib:



Ib

or a pharmaceutically acceptable salt or individual diastereomer thereof.

~~and pharmaceutically acceptable salts thereof and individual diastereomers thereof.~~

- 4-9. canceled

10. (currently amended) The compound of claim 2, 1-wherein R<sup>1</sup> is selected from: -CH(CH<sub>3</sub>)<sub>2</sub>, -C(OH)(CH<sub>3</sub>)<sub>2</sub>, -CH(OH)CH<sub>3</sub> and -CH<sub>2</sub>CF<sub>3</sub>, or a pharmaceutically acceptable salt or individual diastereomer thereof. ~~-and pharmaceutically acceptable salts thereof and individual diastereomers thereof.~~

- 11-12. canceled

13. (currently amended) The compound of claim 2, 12-wherein R<sup>5</sup> is trifluoromethyl, or a pharmaceutically acceptable salt or individual diastereomer thereof. ~~-and pharmaceutically acceptable salts thereof and individual diastereomers thereof.~~

- 14-15. canceled

16. (currently amended) The compound of claim 2, 1-wherein R<sup>16</sup> is selected from: hydrogen, trifluoromethyl, methyl, methoxy, ethoxy, ethyl, fluoro and hydroxy, or a pharmaceutically acceptable salt or individual diastereomer thereof. ~~-and pharmaceutically acceptable salts thereof and individual diastereomers thereof.~~

- 17-23. canceled


24. (currently amended) A pharmaceutical composition which comprises an inert carrier and the ~~a~~ compound of Claim 2, 1-.

25. (withdrawn) A method for ~~modulation~~ modulations of chemokine receptor activity in a mammal which comprises the administration of an effective amount of ~~the -a-~~ compound of Claim 2. ~~1-.~~

26. (withdrawn) A method for treating, ameliorating, controlling or reducing the risk of an inflammatory ~~or~~ and immunoregulatory disorder or disease which comprises the administration to a patient of an effective amount of ~~-a-~~ the compound of Claim 2. ~~1-.~~

27. (withdrawn) A method for treating, ameliorating, controlling or reducing the risk of rheumatoid arthritis which comprises the administration to a patient of an effective amount of ~~-a-~~ the compound of Claim 2. ~~1-.~~

28. (new) A compound selected from:



or a pharmaceutically acceptable salt or individual diastereomer thereof.